Sermonix Pharmaceuticals
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Founded Year
2014Stage
Series A - II | AliveTotal Raised
$72.77MLast Raised
$40M | 9 mos agoAbout Sermonix Pharmaceuticals
Sermonix Pharmaceuticals is a biotechnology company with a targeted focus towards bringing female-specific oncology products through proof of concept, preclinical, and clinical development with a clear regulatory pathway in place.
Sermonix Pharmaceuticals Headquarter Location
3000 East Main St Suite 218
Columbus, Ohio, 43209,
United States
614-864-4919
Expert Collections containing Sermonix Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Sermonix Pharmaceuticals is included in 3 Expert Collections, including Women's Health & Wellness.
Women's Health & Wellness
1,471 items
Startups focused on providing products and services catering to women's health and wellbeing.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Sermonix Pharmaceuticals Patents
Sermonix Pharmaceuticals has filed 2 patents.
The 3 most popular patent topics include:
- Breast cancer survivors
- Estranes
- Hormonal antineoplastic drugs
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
9/7/2021 | Breast cancer survivors, Hormonal antineoplastic drugs, Prodrugs, Synthetic estrogens, Estranes | Application |
Application Date | 9/7/2021 |
---|---|
Grant Date | |
Title | |
Related Topics | Breast cancer survivors, Hormonal antineoplastic drugs, Prodrugs, Synthetic estrogens, Estranes |
Status | Application |
Latest Sermonix Pharmaceuticals News
Jun 21, 2022
Disclosures: Moore reports institutional research fundings from AstraZeneca, Daiichi Sankyo, Roche and Sermonix Pharmaceuticals. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio CHICAGO — Halle Moore, MD, director of breast medical oncology in the department of hematology and oncology at Cleveland Clinic Taussig Cancer Institute, spoke with Healio about findings from the ELAINE 2 study. Results from the study, which assessed a combination of lasofoxifene and abemaciclib in pre- and postmenopausal patients who had ER-positive/HER2-negative metastatic breast cancer and an ESR1 mutation , were presented at ASCO Annual Meeting. “In this trial, in participants who had progression following prior endocrine therapies as well as... up to one line of prior chemotherapy, the combination appeared to be very well tolerated,” Moore said. “Side effects were largely related to the abemaciclib and included gastrointestinal toxicity and cytopenias.” She added that two instances of thrombosis occurred among patients included in the study. “Impressively, however, was the median progression-free survival of 13.9 months that was seen in this refractory metastatic breast cancer population with ESR1 mutations,” Moore said. “So, we were very impressed with the duration of response and the clinical benefit rate in about two-thirds of the patients, who did not have disease progression in the first 24 weeks.” Read more about
Sermonix Pharmaceuticals Web Traffic
Sermonix Pharmaceuticals Rank
When was Sermonix Pharmaceuticals founded?
Sermonix Pharmaceuticals was founded in 2014.
Where is Sermonix Pharmaceuticals's headquarters?
Sermonix Pharmaceuticals's headquarters is located at 3000 East Main St, Columbus.
What is Sermonix Pharmaceuticals's latest funding round?
Sermonix Pharmaceuticals's latest funding round is Series A - II.
How much did Sermonix Pharmaceuticals raise?
Sermonix Pharmaceuticals raised a total of $72.77M.
Who are the investors of Sermonix Pharmaceuticals?
Investors of Sermonix Pharmaceuticals include Xontogeny, Richard DeSchutter, Anthony Wild, Wild Family Office, Lodewijk de Vink and 3 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.